
Cerebral glucose changes after chemotherapy and their relation to long-term cognitive complaints and fatigue
- Author
- Gwen Schroyen, Georg Schramm, Donatienne Van Weehaeghe (UGent) , Nicolas Leenaerts, Thomas Vande Casteele, Jeroen Blommaert, Michel Koole, Ann Smeets, Koen Van Laere, Stefan Sunaert and Sabine Deprez
- Organization
- Abstract
- PurposeTo investigate the short-term cerebral metabolic effects of intravenous chemotherapy and their association with long-term fatigue/cognitive complaints. Experimental designUsing [F-18]-FDG-PET/CT whole-body scans, we retrospectively quantified relative cerebral glucose metabolism before and after neoadjuvant chemotherapy in a cohort of patients treated for non-metastatic breast cancer (2009-2019). Self-report of cognitive complaints and fatigue were prospectively assessed 7 +/- 3 years after therapy. Metabolic changes were estimated with i) robust mixed-effects modelling in regions-of-interest (frontal, parietal, temporal, occipital, and insular cortex) and ii) general-linear modelling of whole-brain voxel-wise outcomes. iii) The association between metabolic changes and self-reported outcomes was evaluated using linear regression-analysis. ResultsOf the 667 screened patients, 263 underwent PET/CT before and after chemotherapy and 183 (48 +/- 9 years) met the inclusion criteria. After chemotherapy, decreased frontal and increased parietal and insular metabolism were observed (|ss|>0.273, p(FDR)<0.008). Separately, additional increased occipital metabolism after epiribucin+ cyclophosphamide (EC) and temporal metabolism after EC+ fluorouracil chemotherapy were observed (ss>0.244, p(FDR)<= 0.048). Voxel-based analysis (p(cluster-FWE)<0.001) showed decreased metabolism in the paracingulate gyrus (-3.2 +/- 3.9%) and putamen (3.1 +/- 4.1%) and increased metabolism in the lateral cortex (L=2.9 +/- 3.1%) and pericentral gyri (3.0 +/- 4.4%). Except for the central sulcus, the same regions showed changes in EC, but not in FEC patients. Of the 97 self-reported responders, 23% and 27% experienced extreme fatigue and long-term cognitive complaints, respectively, which were not associated with metabolic changes. ConclusionBoth hyper- and hypometabolism were observed after chemotherapy for breast cancer. Combined with earlier findings, this study could support inflammatory mechanisms resulting in relative hypermetabolism, mainly in the parietal/occipital cortices. As early metabolic changes did not precede long-term complaints, further research is necessary to identify vulnerable patients.
- Keywords
- Cancer Research, Oncology, fatigue, cognitive complaints, FDG-PET, metabolism, chemotherapy, breast cancer, neuroimaging
Downloads
-
Cerebral glucose changes.pdf
- full text (Published version)
- |
- open access
- |
- |
- 7.04 MB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-01GS556BV955QMM4ZEPX6PA8TB
- MLA
- Schroyen, Gwen, et al. “Cerebral Glucose Changes after Chemotherapy and Their Relation to Long-Term Cognitive Complaints and Fatigue.” FRONTIERS IN ONCOLOGY, vol. 12, Frontiers Media SA, 2022, doi:10.3389/fonc.2022.1021615.
- APA
- Schroyen, G., Schramm, G., Van Weehaeghe, D., Leenaerts, N., Vande Casteele, T., Blommaert, J., … Deprez, S. (2022). Cerebral glucose changes after chemotherapy and their relation to long-term cognitive complaints and fatigue. FRONTIERS IN ONCOLOGY, 12. https://doi.org/10.3389/fonc.2022.1021615
- Chicago author-date
- Schroyen, Gwen, Georg Schramm, Donatienne Van Weehaeghe, Nicolas Leenaerts, Thomas Vande Casteele, Jeroen Blommaert, Michel Koole, et al. 2022. “Cerebral Glucose Changes after Chemotherapy and Their Relation to Long-Term Cognitive Complaints and Fatigue.” FRONTIERS IN ONCOLOGY 12. https://doi.org/10.3389/fonc.2022.1021615.
- Chicago author-date (all authors)
- Schroyen, Gwen, Georg Schramm, Donatienne Van Weehaeghe, Nicolas Leenaerts, Thomas Vande Casteele, Jeroen Blommaert, Michel Koole, Ann Smeets, Koen Van Laere, Stefan Sunaert, and Sabine Deprez. 2022. “Cerebral Glucose Changes after Chemotherapy and Their Relation to Long-Term Cognitive Complaints and Fatigue.” FRONTIERS IN ONCOLOGY 12. doi:10.3389/fonc.2022.1021615.
- Vancouver
- 1.Schroyen G, Schramm G, Van Weehaeghe D, Leenaerts N, Vande Casteele T, Blommaert J, et al. Cerebral glucose changes after chemotherapy and their relation to long-term cognitive complaints and fatigue. FRONTIERS IN ONCOLOGY. 2022;12.
- IEEE
- [1]G. Schroyen et al., “Cerebral glucose changes after chemotherapy and their relation to long-term cognitive complaints and fatigue,” FRONTIERS IN ONCOLOGY, vol. 12, 2022.
@article{01GS556BV955QMM4ZEPX6PA8TB, abstract = {{PurposeTo investigate the short-term cerebral metabolic effects of intravenous chemotherapy and their association with long-term fatigue/cognitive complaints. Experimental designUsing [F-18]-FDG-PET/CT whole-body scans, we retrospectively quantified relative cerebral glucose metabolism before and after neoadjuvant chemotherapy in a cohort of patients treated for non-metastatic breast cancer (2009-2019). Self-report of cognitive complaints and fatigue were prospectively assessed 7 +/- 3 years after therapy. Metabolic changes were estimated with i) robust mixed-effects modelling in regions-of-interest (frontal, parietal, temporal, occipital, and insular cortex) and ii) general-linear modelling of whole-brain voxel-wise outcomes. iii) The association between metabolic changes and self-reported outcomes was evaluated using linear regression-analysis. ResultsOf the 667 screened patients, 263 underwent PET/CT before and after chemotherapy and 183 (48 +/- 9 years) met the inclusion criteria. After chemotherapy, decreased frontal and increased parietal and insular metabolism were observed (|ss|>0.273, p(FDR)<0.008). Separately, additional increased occipital metabolism after epiribucin+ cyclophosphamide (EC) and temporal metabolism after EC+ fluorouracil chemotherapy were observed (ss>0.244, p(FDR)<= 0.048). Voxel-based analysis (p(cluster-FWE)<0.001) showed decreased metabolism in the paracingulate gyrus (-3.2 +/- 3.9%) and putamen (3.1 +/- 4.1%) and increased metabolism in the lateral cortex (L=2.9 +/- 3.1%) and pericentral gyri (3.0 +/- 4.4%). Except for the central sulcus, the same regions showed changes in EC, but not in FEC patients. Of the 97 self-reported responders, 23% and 27% experienced extreme fatigue and long-term cognitive complaints, respectively, which were not associated with metabolic changes. ConclusionBoth hyper- and hypometabolism were observed after chemotherapy for breast cancer. Combined with earlier findings, this study could support inflammatory mechanisms resulting in relative hypermetabolism, mainly in the parietal/occipital cortices. As early metabolic changes did not precede long-term complaints, further research is necessary to identify vulnerable patients.}}, articleno = {{1021615}}, author = {{Schroyen, Gwen and Schramm, Georg and Van Weehaeghe, Donatienne and Leenaerts, Nicolas and Vande Casteele, Thomas and Blommaert, Jeroen and Koole, Michel and Smeets, Ann and Van Laere, Koen and Sunaert, Stefan and Deprez, Sabine}}, issn = {{2234-943X}}, journal = {{FRONTIERS IN ONCOLOGY}}, keywords = {{Cancer Research,Oncology,fatigue,cognitive complaints,FDG-PET,metabolism,chemotherapy,breast cancer,neuroimaging}}, language = {{eng}}, pages = {{13}}, publisher = {{Frontiers Media SA}}, title = {{Cerebral glucose changes after chemotherapy and their relation to long-term cognitive complaints and fatigue}}, url = {{http://doi.org/10.3389/fonc.2022.1021615}}, volume = {{12}}, year = {{2022}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: